Cephradine

Summary

Cephradine (CHEMBL1604) is an approved small-molecule antibacterial drug (ATC J01DB09); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DB09
• Indications: 1 condition
• Chemistry: 349.4 Da · C16H19N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1604
Name	Cephradine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	38103
ChEBI	CHEBI:3547
ATC	J01DB09
Molecular formula	C16H19N3O4S
Molecular weight	349.4
InChIKey	RDLPVSKMFDYCOR-UEKVPHQBSA-N

SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Anspor, Cefradina, Cefradine, Cefradine hydrate, Cephradine, Cephradine anhydrous, Cephradine hydrate, unspecified hydrate, Ecosporina, Nicef, NSC-756672, SK&F D-39304

Parent form; salt/anhydrous children: CHEMBL4303427

Patent coverage: 5,995 distinct patent families (20,133 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Progesterone receptor, Prostaglandin G/H synthase 2, Adenosine receptor A3, Solute carrier family 15 member 2, Nuclear receptor subfamily 1 group I member 2, Solute carrier family 15 member 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS2	5.13	AC50	7400	nM	CHEMBL_ACT_25166180
SLC15A1	5.01	Ki	9800	nM	CHEMBL_ACT_10996718

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).